Abstract: A method for treating metabolic disorders in non-infant includes administering to an obese non-infant human during a treatment period an effective amount of a mixture of two or more synthetic neutral human milk oligosaccharides (HMOs) selected from 2?-fucosyllactose (2?FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), and lacto-N-neotetraose (LNnT), and optionally one or more excipients. The method further includes increasing in the gastrointestinal microbiota of the non-infant human during the treatment period, the relative abundance of Bifidobacterium adolescentis and reducing in the non-infant human during the treatment period, a precursor condition for a metabolic disorder associated with development of one or more of obesity-induced pre-diabetes and type 2 diabetes, the precursor condition selected from gut permeability, metabolic endotoxemia, low-grade metabolic inflammation, and body fat percentage.

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

Abstract: The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient a mixture comprising 2?-fucosyllactose (2?-FL) and lacto-N-neotetraose (LNnT).

Abstract: The application relates to synthetic composition containing one or more human milk mono- or oligosaccharides which promote mucosal healing in inflammatory GI conditions of humans.

Abstract: The application relates to synthetic compositions containing one or more human milk oligosaccharides for regulating satiety or reducing propensity to obesity.

Abstract: The invention relates to a method for stabilising or reducing insulin resistance in patients having an obesity-related, metabolic disorder, the method comprising administering to the patient an effective amount of one or more human milk oligosaccharides (HMOs).

Abstract: The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for use treating irritable bowel syndrome.

Abstract: The invention relates to a synthetic composition comprising one or more human milk monosaccharides and/or one or more human milk oligosaccharides for use in reducing intestinal permeability, endotoxemia and/or low-grade inflammation in patients with metabolic disorders.

Abstract: The invention relates to HMOs and compositions comprising thereof for reducing the risk of, preventing, or treating CVD and/or CDV associated pathological conditions or diseases in humans, particularly in overweight and obese humans.

Abstract: The invention relates to a method for treating or preventing the development of emotion and/or mood disorders in a human individual.

Abstract: The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for treating visceral pain.

Abstract: The application relates to synthetic compositions containing one or more human milk mono- or oligosaccharides for treating non-infectious diarrhoea.